Skip to main content

Table 6 Treatment-emergent adverse events

From: Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

 

Anidulafungin n = 43

 

All-causality

Treatment-related

Number of adverse events

150

12

Subjects with adverse events

35

9

Subjects with serious adverse events

16

1

Subjects with severe adverse events

13

0

Subjects discontinued due to adverse events

3

3

Subjects with dose reduced or temporary discontinuations due to adverse events

2

1

Deaths, n (%)

 

  All causality

10 (23.3)